Top brand choice
Strength | Pack Size | Qty | |
---|---|---|---|
Strength
25mg
|
|||
Strength
50mg
|
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Myrbetriq is prescribed for treating adults with overactive bladder (OAB) accompanied by symptoms of urgency, urge urinary incontinence, and urinary frequency.
Myrbetriq is also prescribed for treating pediatric patients who are 3 years of age and older with neurogenic detrusor overactivity (NDO) and weigh 35 kg or more.
Myrbetriq 25 mg extended-release tablets and Myrbetriq 50 mg extended-release tablets (mirabegron extended-release tablets) for oral administration may be dispensed upon receipt of a valid prescription.
Fact Table | |
---|---|
Formula | C21H24N4O2S |
License | FDA approved |
Bioavailability | 29-35% (varies with dosage) |
Legal status | Prescription only |
Chemical Name | 2-(2-Amino-1,3-thiazol-4-yl)-N-[4-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]phenyl]acetamide |
Elimination half-life | Approximately 50 hours |
Dosage (Strength) | 25 mg, 50 mg tablets |
Pregnancy | Consult a healthcare provider |
Brands | Myrbetriq |
Protein binding | 71% |
PubChem CID | 9869929 |
MedlinePlus | a613042 |
ChEBI | 70782 |
ATC code | G04BD12 |
DrugBank | DB04899 |
KEGG | D08876 |
Routes of administration | Oral |
Myrbetriq should be taken as your doctor has directed. Carefully read the medication guide that comes with your prescription for further instructions for use.
Adults with OAB are recommended to start out on a 25 mg dose by mouth once daily. After 4-8 weeks, the dose may be increased to a 50 mg dose by mouth once daily.
A doctor will provide dosing for pediatric patients who have NDO, which is dependent upon weight.
Storage: 20°C to 25°C (68°F to 77°F).
Any questions or concerns about Myrbetriq may be referred to your doctor or pharmacist.
Mirabegron is the active ingredient in Myrbetriq.
Myrbetriq tablets contain the following inactive ingredients: butylated hydroxytoluene, hydroxypropyl cellulose, hypromellose, magnesium stearate, polyethylene glycol, polyethylene oxide, red ferric oxide (only the 25 mg tablet), and yellow ferric oxide.
Myrbetriq should not be administered to patients who are allergic to mirabegron or to any of its inactive ingredients.
Myrbetriq side effects include but are not limited to common cold, constipation, dry mouth, headache, high blood pressure, rapid heart rate, and urinary tract infection. If you have bothersome or persistent side effects, inform your doctor right away.
Here, you can buy Myrbetriq.
Myrbetriq. Northbrook, IL: Astellas Pharma US, Inc.; 2021.